Details

Autor(en) / Beteiligte

• Wang, Zong-Ren
• Wei, Jin-Huan
• Zhou, Jian-Cheng
• Haddad, Ahmed
• Zhao, Liang-Yun
• Kapur, Payal
• Wu, Kai-Jie
• Wang, Bin
• Yu, Yan-Hong
• Liao, Bing
• He, Da-Lin
• Chen, Wei
• Margulis, Vitaly
• Hsieh, Jer-Tsong
• Luo, Jun-Hang

Titel

Validation of DAB2IP methylation and its relative significance in predicting outcome in renal cell carcinoma

Ist Teil von

• Oncotarget, 2016-05, Vol.7 (21), p.31508-31519

Ort / Verlag

United States: Impact Journals LLC

Erscheinungsjahr

2016

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• We have recently reported tumor suppressive role of DAB2IP in RCC development. In this study, We identified one CpG methylation biomarker (DAB2IP CpG1) located UTSS of DAB2IP that was associated with poor overall survival in a cohort of 318 ccRCC patients from the Cancer Genome Atlas (TCGA). We further validated the prognostic accuracy of DAB2IP CpG methylation by pyrosequencing quantitative methylation assay in 224 ccRCC patients from multiple Chinese centers (MCHC set), and 239 patients from University of Texas Southwestern Medical Center at Dallas (UTSW set) by using FFPE samples. DAB2IP CpG1 can predict the overall survival of patients in TCGA, MCHC, and UTSW sets independent of patient age, Fuhrman grade and TNM stage (all p<0.05). DAB2IP CpG1 successfully categorized patients into high-risk and low-risk groups with significant differences of clinical outcome in respective clinical subsets, regardless of age, sex, grade, stage, or race (HR: 1.63-7.83; all p<0.05). The detection of DAB2IP CpG1 methylation was minimally affected by ITH in ccRCC. DAB2IP mRNA expression was regulated by DNA methylation in vitro. DAB2IP CpG1 methylation is a practical and repeatable biomarker for ccRCC, which can provide prognostic value that complements the current staging system.